EQT Corporation (NYSE:EQT) ("EQT" or the "Company") today announced that the U.S. Federal Trade Commission (the "FTC") has resolved its review of EQT's agreement with THQ
Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific Officer Miles Nunn will present a